In this video, Professor Pablo Foncillas addresses the future of clinical trials, which may enter a new era with "synthetic patients" powered by artificial intelligence (AI).
"Generative AI, once again, is about to give a facelift to a new sector, that of clinical trials. No more real humans for the control group. In their place, there will be virtual humans, created by an algorithm that has devoured medical records from a diverse patient population," says the researcher.
And what does it mean for AI to come into play? "As confirmed by Lloyd Minor, dean of the Stanford School of Medicine, it could unlock a new world in the pharmaceutical sector, where drugs would be approved faster and where trial costs would be reduced," continues Foncillas. Added to this is the ability of AI to discover new antibiotics in record time.
However, problems such as long waiting periods or the low availability of health system professionals do not seem to have such an easy resolution.
What impact can all this have on healthcare? Will the future be better with AI? The answer, in the video...
